NXN
Nexsen Ltd
$0.1400
0.00%
Market cap
$13M
Turnover
$98,158
Last price
$0.1400
Day change
0.00%
Announcements
13
Range, past year
Open 0.255 · Low 0.130 · Now 0.140 · High 0.345
Open NXN in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
NXN momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
33/100
Wyckoff phase
Downtrend2d
Trend stage
Breakdown
1 Day
+0.0%
1 Week
-15.2%
1 Month
-30.0%
RSI
22
Avg daily range
15.1%
Nexsen Ltd scores 33 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 2 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- Trend R² 0.93 — highly linear uptrend
Points to watch
- RSI oversold (22)
- 60d drawdown -57.6%
- High volatility (ATR 15.1%)
- Thin liquidity
- Risk rating: Very High
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsNXN announcements
Recent price-sensitive releases.
- 2026-09-25 Proposed FlashDx joint venture builds on CE-marked GBS test Progress Report
- 2026-09-25 Reinstatement to Quotation Reinstatement to Official Quotation
- 2026-09-24 Suspension from Quotation Suspension from Official Quotation
- 2026-09-24 Clear pathway defined to optimise StrepSure Progress Report
- 2026-09-22 Trading Halt Trading Halt
- 2026-08-31 Annual Report - FY 2026 Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-29 Quarterly Report - Q4 FY26 Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
More Health Care stocks
Most traded in the same sector.